Choi Kyung-jung's Dementia Treatment Costs Also Covered... Heungkuk Fire & Marine Insurance Launches Industry's First Caregiving Insurance

Coverage for Targeted Dementia Treatment Costs
Including Mild Alzheimer's Dementia

Taekwang Group's financial affiliate, Heungkuk Fire & Marine Insurance, has introduced the industry's first long-term care insurance product that covers 'treatment costs for very mild dementia.'

On the 22nd, Heungkuk Fire & Marine Insurance announced the launch of the 'HeungGood Family Love Simple Dementia Care Insurance.' This long-term care insurance product guarantees treatment costs for targeted dementia, including very mild dementia (CDR 0.5 points) and mild Alzheimer's dementia.

The targeted dementia drug-approved treatment cost rider covers medication costs such as for Leqembi. According to Heungkuk Fire & Marine Insurance, Leqembi is a drug that removes amyloid beta protein, known as the causative substance of Alzheimer's. It is known as a drug that can fundamentally treat dementia beyond just slowing its progression. It shows treatment effects at the very mild dementia and mild Alzheimer's stages.

To receive insurance benefits, a diagnosis of very mild dementia or mild Alzheimer's dementia must be made, and it must be confirmed that amyloid beta protein has accumulated in the brain to a certain level. If the conditions are met and the treatment is administered more than seven times, treatment costs up to 10 million KRW will be paid for the first administration only.

The rider also covers other drugs with the same effect that may be developed in the future besides Leqembi. The coverage scope and period have been expanded to strengthen long-term care coverage due to dementia.

Optional riders such as 'day and night care' and 'home care' can also be subscribed to. The 'welfare equipment' rider covers costs for purchasing or renting welfare equipment such as wheelchairs or walking aids.

A Heungkuk Fire & Marine Insurance official said, "This is the industry's first product to pay insurance benefits in cash at the very mild dementia stage, and we have also obtained exclusive usage rights related to targeted dementia drug-approved treatment costs until September. It is expected to significantly reduce the burden of dementia treatment costs."